Search
Linsitinib
go.drugbank.com/drugs/DB06075InvestigationalAn orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigationalZiftomenib is a potent and highly selective menin inhibitor. … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.
BACTEK-R
go.drugbank.com/drugs/DB16526InvestigationalThough studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood.
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation
AdPEDF
go.drugbank.com/drugs/DB05138ExperimentalIt has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors
Adafosbuvir
go.drugbank.com/drugs/DB14906InvestigationalAdafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335).
GW-468816
go.drugbank.com/drugs/DB15099ExperimentalGW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).
Davanat
go.drugbank.com/drugs/DB15311InvestigationalDavanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).
ABT-560
go.drugbank.com/drugs/DB06093ExperimentalABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.
BTA9881
go.drugbank.com/drugs/DB05226InvestigationalBTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.